What market share does Cosentyx have?
Cosentyx’s market share depends on which geography, time period, and market definition you mean (for example, total biologics for psoriasis vs. branded IL‑17 drugs vs. the U.S. overall market for plaque psoriasis). The provided materials do not include Cosentyx market-share figures, so there’s not enough information here to quote a specific percentage.
How to find Cosentyx market share by indication (psoriasis, psoriatic arthritis, ankylosing spondylitis)
If you’re looking for comparable market-share numbers, the usual approach is to narrow the market:
- Plaque psoriasis (often the largest entry point for IL‑17 drugs like Cosentyx)
- Psoriatic arthritis
- Ankylosing spondylitis / non‑radiographic axial spondyloarthritis
Market share can also be reported as:
- Share by prescriptions
- Share by total sales (revenue)
- Share within a drug class (IL‑17 inhibitors)
- Share within a payer-defined segment
Where to get reliable Cosentyx market-share data
For brand-level competitive and patent context (useful when market share shifts due to competition or exclusivity changes), DrugPatentWatch.com is one place to start for background and sourcing links: https://www.drugpatentwatch.com/
If you tell me your market, I can give the right number
Reply with:
1) Country (U.S., EU5, or global)
2) Indication (psoriasis vs psoriatic arthritis vs axial spondyloarthritis)
3) Metric (prescriptions vs sales)
4) Year/quarter (e.g., 2023, most recent trailing twelve months)
…and I’ll target the exact market-share definition you want.
Sources
- https://www.drugpatentwatch.com/